COLL - Collegium Pharmaceutical GAAP EPS of -$0.39 revenue of $83.75M

Collegium Pharmaceutical press release (NASDAQ:COLL): Q1 GAAP EPS of -$0.39. Revenue of $83.75M (-4.5% Y/Y). 2022 Guidance: Total product revenues are expected in the range of $450.0 million to $465.0 million, up approximately 65% at the midpoint compared to net product revenue of $276.9 million in 2021; Total adjusted operating expenses, which excludes stock-based compensation expense and acquisition related expenses, are expected in the range of $130.0 million to $140.0 million; and Total adjusted EBITDA is expected in the range of $235.0 million to $250.0 million.

For further details see:

Collegium Pharmaceutical GAAP EPS of -$0.39, revenue of $83.75M